Overview
Aspirated substance-related disorders (ASRD) in the lower respiratory tract encompass a spectrum of inflammatory conditions characterized by aberrant eicosanoid metabolism and heightened immune responses. These conditions often manifest as chronic respiratory tract inflammation, including chronic eosinophilic rhinosinusitis, nasal polyposis, and asthma, with notable exacerbations triggered by aspirin and cyclooxygenase (COX)-1 inhibitors. Understanding the pathophysiology, clinical presentation, diagnosis, differential diagnosis, management, and potential complications is crucial for effective patient care. This guideline synthesizes evidence from key studies to provide a comprehensive clinical framework for managing ASRD.
Pathophysiology
The pathogenesis of ASRD is multifaceted, involving dysregulation in eicosanoid biosynthesis and receptor expression, alongside significant infiltration of mast cells and eosinophils throughout the respiratory tract [PMID:19575683]. Eicosanoids, including prostaglandins and leukotrienes, play pivotal roles in modulating inflammation and airway responsiveness. Abnormalities in their production and signaling pathways contribute to the persistent inflammatory state observed in ASRD. Mast cells, known for their role in allergic reactions, release mediators such as histamine and cytokines that exacerbate airway inflammation. Similarly, eosinophilic infiltration is a hallmark of ASRD, reflecting a Th2-type immune response characterized by elevated levels of IL-5 and other cytokines that promote eosinophil recruitment and activation [PMID:19575683]. This complex interplay of cellular and molecular mechanisms underscores the need for targeted therapeutic interventions aimed at modulating these pathways.
Clinical Presentation
ASRD typically presents with a constellation of respiratory symptoms reflecting chronic inflammation affecting both the upper and lower respiratory tracts. Patients often experience persistent cough, wheezing, shortness of breath, and recurrent respiratory infections. Chronic eosinophilic rhinosinusitis and nasal polyposis may coexist, contributing to nasal congestion, facial pain, and altered sense of smell [PMID:19575683]. Exacerbations, particularly those triggered by aspirin and COX-1 inhibitors, can lead to acute worsening of symptoms, including severe bronchospasm and respiratory distress. In equine models, studies have shown a positive correlation between neutrophil percentages in tracheal aspirates (TA) and broncho-alveolar lavage fluid (BALF) and the extent of mucus accumulation, indicative of heightened neutrophilic inflammation in conditions like Recurrent Airway Obstruction (RAO) and Inflammatory Airway Disease (IAD) [PMID:26618592]. These findings suggest that monitoring inflammatory cell profiles can provide valuable insights into disease activity and response to treatment.
Diagnosis
Diagnosing ASRD involves a combination of clinical evaluation, laboratory tests, and imaging studies. Endoscopic examination and bronchoalveolar lavage (BAL) are particularly informative in assessing the extent of airway inflammation and mucus production. In horses with RAO and IAD, a positive correlation between neutrophil percentages in TA and BALF and the observed endoscopic mucus accumulation highlights the utility of these diagnostic tools [PMID:26618592]. For human patients, spirometry can reveal obstructive patterns consistent with asthma, while sputum analysis may demonstrate eosinophilia, supporting the diagnosis of ASRD. Additionally, provocation tests with aspirin or COX inhibitors can confirm sensitivity, although these should be conducted cautiously due to the risk of severe reactions. The differential diagnosis must consider other inflammatory airway diseases and hypersensitivity reactions, where eosinophil percentages in BALF inversely correlate with mucus accumulation, offering a potential diagnostic clue [PMID:26618592]. Clinicians should also consider selective COX-2 inhibitors as a safer alternative in managing symptoms, given that patients with aspirin sensitivity often tolerate these better [PMID:19575683].
Differential Diagnosis
Differentiating ASRD from other respiratory conditions is essential for appropriate management. Conditions such as chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and primary eosinophilic pneumonia share overlapping symptoms but differ in underlying mechanisms and specific inflammatory profiles. In horses, the inverse relationship between eosinophil counts in BALF and mucus accumulation can help distinguish IAD from other respiratory disorders characterized by higher eosinophil infiltration [PMID:26618592]. For human patients, distinguishing ASRD from aspirin-exacerbated respiratory disease (AERD) is critical, as both involve aspirin sensitivity but differ in clinical presentation and response to therapy. AERD typically presents with more pronounced nasal and sinus symptoms alongside asthma, whereas ASRD may encompass a broader spectrum of respiratory involvement. Clinicians should also consider environmental and occupational exposures that can mimic or exacerbate ASRD symptoms, necessitating thorough patient history and exposure assessments.
Management
The management of ASRD aims to control inflammation, prevent exacerbations, and improve quality of life. Pharmacological interventions often include inhaled corticosteroids to reduce airway inflammation and bronchodilators to manage bronchospasm. Leukotriene receptor antagonists may be beneficial due to their role in modulating eicosanoid-mediated inflammation [PMID:19575683]. In cases of aspirin sensitivity, selective COX-2 inhibitors are preferred over traditional NSAIDs to avoid triggering exacerbations. Desensitization protocols, involving gradual aspirin administration under strict medical supervision, have shown promise in achieving long-term clinical improvement in many patients [PMID:19575683]. Lifestyle modifications, such as avoiding known triggers and maintaining optimal environmental conditions (e.g., reducing allergen exposure), are also crucial. Pulmonary rehabilitation programs can enhance respiratory muscle strength and overall functional capacity, contributing to better symptom management and reduced hospitalizations. Regular follow-up and monitoring of inflammatory markers and symptom control are essential to tailor treatment adjustments effectively.
Complications
ASRD carries significant risks of complications, particularly when exacerbated by aspirin and COX-1 inhibitors. Ingestion of these substances can precipitate severe respiratory distress, including acute bronchospasm, respiratory failure, and potentially life-threatening exacerbations [PMID:19575683]. Chronic inflammation can also lead to structural changes in the airways, such as bronchial remodeling, which may impair lung function over time. Additionally, recurrent infections due to compromised airway defenses pose a substantial risk. Patients with ASRD are advised to strictly avoid aspirin and non-selective NSAIDs to prevent such exacerbations. Early recognition and aggressive management of complications are vital to mitigate long-term morbidity and improve patient outcomes.
Key Recommendations
References
1 Wysocka B, Kluciński W. Cytological evaluation of tracheal aspirate and broncho-alveolar lavage fluid in comparison to endoscopic assessment of lower airways in horses with recurrent airways obstruction or inflammatory airway disease. Polish journal of veterinary sciences 2015. link 2 Farooque SP, Lee TH. Aspirin-sensitive respiratory disease. Annual review of physiology 2009. link
2 papers cited of 8 indexed.